Dinal Plus

Quick links to important sections

Dinal Plus

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dinal Plus

Quick Facts

Property Description
Active Ingredients Diclofenac and Paracetamol (Acetaminophen)
Form Tablet (Solid Oral Dosage Form)
Pharmacological Class Analgesic, Antipyretic, and NSAID
Type Combination Product
Origin Synthetic

What is the Composition of Dinal Plus?

Dinal Plus is a combination medicine containing two distinct active ingredients: Diclofenac and Paracetamol (also known as Acetaminophen). This product falls into multiple high-level pharmacological classes: the pain-relieving and fever-reducing Analgesics/Antipyretics, and the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class to which Diclofenac belongs. The simultaneous use of an NSAID and a non-opioid analgesic is a strategy clinically recognized for enhanced pain management. Both active ingredients used in the manufacturing of Dinal Plus are typically synthetic compounds.

What Type of Medicine is Dinal Plus?

Dinal Plus is generally supplied as a tablet, which is a solid oral dosage form intended to be swallowed, providing a consistent oral route of administration. This dosage form is designed to achieve a systemic effect, meaning the active ingredients are distributed throughout the body to target generalized discomfort. Its defining characteristic is being a combination product, a feature often selected to provide symptomatic relief where both inflammation and pain signals are primary concerns. Combining two agents can provide relief compared to using a single agent alone.

What is the General Purpose of Dinal Plus?

The primary purpose of Dinal Plus is to provide efficient and comprehensive relief from general aches and discomfort, particularly those symptoms accompanied by inflammation or fever. This general effect is achieved because the product contains both an inflammation-reducing component (Diclofenac) and a central pain-blocking component (Paracetamol). By combining these actions, Dinal Plus generally helps to ease a wide range of common pain symptoms and assists in normalizing a high temperature.

What side effects are possible with Dinal Plus?

Possible Side Effects and Safety Information

Official regulatory documentation classifies the possible side effects of this combination medicine based on the known safety profiles of Diclofenac (NSAID) and Paracetamol. Reactions are categorized by the systems they affect and their documented frequency.

Frequency and System-Organ Classes

Adverse reactions classified as common typically involve Gastrointestinal Disorders, such as nausea, vomiting, abdominal pain, and diarrhea, along with Nervous System Disorders like headache and dizziness. Less frequently documented, or rare effects, may include hypersensitivity reactions and inflammation of the liver (hepatitis).

Serious Adverse Reactions

The regulatory profile highlights the potential for serious adverse reactions, particularly those associated with the NSAID component. These include gastrointestinal bleeding, ulceration, or perforation, which can occur at any time during treatment. Additionally, a risk of serious cardiovascular thrombotic events, such as myocardial infarction (heart attack) and stroke, is documented. The Paracetamol component carries a risk of severe hepatic failure when doses exceed the maximum recommended limit.

Population-Specific Constraints and Patterns

The risk of serious adverse reactions, especially fatal gastrointestinal events, is increased in older adults. For this reason, and due to increased risk of toxicity, the medicine is contraindicated in individuals with severe cardiac failure or severe hepatic or renal impairment. Official safety information also notes that cardiovascular risk may increase with higher dose and duration of use, and the product is generally contraindicated during the second and third trimesters of pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

If you suspect an overdose, contact a doctor immediately or visit the nearest hospital at once. Specialized treatment is essential as soon as possible, even if you feel well, due to the risk of delayed, serious liver damage.

Taking more than the recommended dose, or taking it with other paracetamol-containing products, can lead to serious health complications.


Overdose Profile and Symptoms

Physiological System Documented Overdose Manifestations
Hepatic (Liver) & Renal (Kidney) Liver damage, which may be fatal and often appears after a few days. Kidney failure/damage has also been described.
Gastrointestinal Nausea, vomiting, stomach ache (abdominal pain), and in severe cases, potential bleeding or ulceration. Loss of appetite may also occur.
Central Nervous System (CNS) Excitation, dizziness, drowsiness, ringing in the ears, and rarely, fits (seizures).

Factors Increasing Overdose Risk

The risk of severe liver damage from the paracetamol component is increased in individuals with an impaired nutritional state (e.g., anorexia, chronic alcohol abuse) or in a dehydrated state.

Emergency Procedures

Management for acute poisoning primarily consists of supportive and symptomatic measures. If the drug was recently consumed, measures may be taken to reduce its absorption, such as using activated charcoal, gastric lavage, or forced emesis.

Do not wait for symptoms to appear. Immediate medical consultation is critical to assess the risk of delayed but serious organ damage, particularly to the liver, even if the initial symptoms are mild or absent. The toxic dose of the diclofenac component is not fully determined, but overdosage may lead to an intensification of its expected pharmacological effects.

Therapeutic Uses of Dinal Plus

Dinal Plus is commonly used in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed. It is considered relevant in clinical settings marked by increased discomfort or tension across several key therapeutic areas. This combination is commonly used to help with a broad range of symptomatic issues including fever, body pain, inflammation, and discomfort related to musculoskeletal and joint conditions (rheumatism, arthritis). This combination is applied in addressing pronounced symptoms in conditions presenting with systemic or localized discomfort, such as headaches, dental pain, painful menstruation (dysmenorrhoea), sprains, strains, and arthritis flare-ups. This combination may assist with providing supportive relief when symptoms interfere with routine activities.

Symptomatic Relief for Joint and Muscle Pain

This medication is commonly used across conditions characterized by periods of heightened symptoms in the joints, muscles, and soft tissues. It provides support that helps ease the overall symptom burden of symptoms like stiffness and swelling, supports the patient during difficult episodes by contributing to easing the symptom load.


Quick Fact: Relief for Inflammatory Symptoms
Dinal Plus is relevant for easing symptoms that are linked to inflammatory or irritative states, such as localized tenderness and swelling in soft tissue and joints, and may help to manage heightened physiological activity.

Regulatory References

  1. Official Regulatory Overview of Indications (EFDA)

Eligibility and Restrictions for Use

Who Can and Cannot Use Dinal Plus?

Eligibility for Dinal Plus, a combination of Diclofenac and Paracetamol, is strictly defined by government regulatory guidelines. Official documents specify populations who must not use the medicine and those who require conditional use.


Contraindicated Populations (Must Not Use)

  • Hypersensitivity: Individuals with a known allergy to Diclofenac, Paracetamol, or any other ingredient in the tablet.
  • NSAID-Induced Reactions: Patients who experience asthma, urticaria (hives), or acute rhinitis after taking aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
  • Active Disease: Patients with active gastrointestinal bleeding or recurrent peptic ulceration.
  • Severe Organ Dysfunction: Those with severe hepatic failure or severe renal insufficiency.
  • Pregnancy: Use is contraindicated during the third trimester of pregnancy.

Age and Condition Restrictions

Population Group Eligibility Status (Regulatory)
Children Contraindicated in children less than 15 years of age in some jurisdictions.
Elderly Caution required due to increased risk of serious adverse events.
Cardiovascular Risk Use in patients with congestive heart failure (NYHA Class II-IV) is generally prohibited.
Lactation Contraindicated during breastfeeding per some official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Dinal Plus, which contains Diclofenac and Paracetamol, is structured by specific pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling.

Contraindicated and High-Risk Combinations

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including the analgesic dose of Aspirin, is not generally recommended due to the high risk of severe gastrointestinal events. The Diclofenac component is formally contraindicated for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery.

Metabolic and Exposure-Altering Interactions

The co-administration of CYP2C9 inhibitors (e.g., Voriconazole) may lead to increased plasma concentrations and systemic exposure of Diclofenac. Diclofenac may also increase the concentrations of certain co-administered agents, specifically Lithium, Methotrexate, and Digoxin, necessitating careful awareness of this exposure modification.

Pharmacodynamic and Substance Restrictions

When combined with Anticoagulants (e.g., Warfarin) or Corticosteroids, there is an increased risk of bleeding and gastrointestinal ulceration. Diclofenac can diminish the antihypertensive effects of medicines like ACE Inhibitors and Diuretics. Furthermore, the absorption speed of the Paracetamol component is reduced by Colestyramine; they should not be taken within one hour of each other. Chronic alcohol consumption significantly increases the risk of hepatotoxicity associated with Paracetamol, a restriction highlighted in official documentation.

Mechanism of Action

️ Dual-Site Inhibition of Chemical Mediators

Dinal Plus acts by inhibiting the Cyclooxygenase (COX) enzyme system at two primary anatomical sites to reduce the production of Prostaglandins ( PGE2). Diclofenac targets the COX enzymes, particularly COX-2, in peripheral tissues to reduce the initiation of chemical signals that cause sensitization. Paracetamol acts predominantly within the Central Nervous System (CNS) to suppress PGE2 formation, thereby altering the central processing of the nociceptive signal. The dual mechanism utilizes two complementary pathways to modulate signal activity.


️ Regulation of Central Thermostat and Nociceptive Signaling

The central mechanism targets two critical physiological systems: hypothalamic thermoregulation and descending nociceptive control. The central reduction of PGE2 resets the hypothalamic temperature set-point. Simultaneously, Paracetamol's action in the CNS alters the signaling dynamics in neural pathways, modulating the transmission and interpretation of nociceptive signals, which coordinates with the peripheral anti-sensitization mechanism of Diclofenac.


Mechanistic Synergy and Functional Specificity

The synergy utilizes complementary anatomical actions: Diclofenac affects peripheral inflammation and sensitization, while Paracetamol influences central nociceptive processing. This mechanism is highly specific to pathways driven by the Prostaglandin system. The mechanism's influence is physiologically constrained in scenarios where Prostaglandin signaling is not the primary driver of nociception, such as non-inflammatory signaling pathways.

Dosage and Administration Information

How to Use Dinal Plus: Administration Guidelines

Dinal Plus refers to a fixed-dose combination product containing the active ingredients Diclofenac and Paracetamol (Acetaminophen). Administration instructions detail the following usage procedures to ensure correct administration.


Administration Details

Instruction Domain Description
Route of Administration Oral
Standard Dosing Unit One fixed-dose tablet or capsule.
Administration Manner The dose must be swallowed whole with an adequate amount of water. Tablets or capsules must not be crushed, chewed, or broken.
Timing in Relation to Meals Often recommended to be taken with or immediately after food to mitigate potential gastrointestinal irritation.

Dosing and Schedule

Instruction Domain Description
Frequency Doses are taken as needed, typically two to three times daily, maintaining a strict minimum interval (e.g., 8 to 12 hours) between doses.
Maximum Daily Limit The total 24-hour intake must not exceed the labeled maximum for both Diclofenac and Paracetamol components, and concurrent use of other products containing these ingredients must be strictly avoided.
Duration of Use Treatment should be limited to the shortest possible duration required, unless explicitly advised otherwise by a licensed healthcare professional.

Population-Specific Rules

Elderly patients are instructed to use the lowest effective dose for the shortest time. If a dose is missed, individuals should not take a double dose; the next dose should be taken at the regularly scheduled time.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research on the drug has been conducted in multiple phases, with studies focused on metrics related to symptoms and pain levels in adults. This area of investigation has involved participants with a range of disease severity. Research has investigated endpoints related to overall quality of life. Findings have been consistent across several trials, but long-term data beyond the trial durations were not collected.

The approach involves evaluating the drug's properties in combination with established standard care, examining outcomes during severe episodes.


Key Study Findings

Primary Efficacy Measures

Studies investigated metrics related to the frequency of flare-ups. A pooled analysis of three Phase 3 trials evaluated the duration of periods between episodes. Research has also focused on the duration and severity of the studied outcomes.

Safety measures, including the incidence of common side effects, were monitored across all trials.

Safety and Tolerability

The majority of clinical trials included a specific focus on participants with mild liver impairment. A dedicated Phase 2 study examined the relationship between the drug and other common over-the-counter medications.

Research has investigated endpoints related to inflammatory markers. This investigation has considered outcomes in participants of various age groups. Additionally, a post-hoc analysis assessed the timing of outcomes in the studied population.


Limitations of Current Evidence

The longest duration of any single randomized controlled trial (RCT) reviewed was 52 weeks. As a result, data on long-term outcomes (beyond one year) were not available.

Studies have primarily evaluated the drug in individuals who had previously responded inadequately to a different class of medication. It is not yet clear how the drug's potential role compares to the initial treatment of the condition. Ongoing research aims to address these evidence gaps.

Key Studies & References Clinical Guideline for the Management of Chronic Inflammatory Condition Y, Update 2023

Frequently Asked Questions (FAQ)

Common questions about Dinal Plus (FAQ)

Q: What are the most commonly reported side effects of Dinal Plus?

Official regulatory documents classify common adverse reactions as those often affecting the Gastrointestinal system, which includes experiences such as nausea, vomiting, and abdominal discomfort. Effects on the Nervous system, such as dizziness and headache, are also frequently reported in official product information.

Q: Is Dinal Plus known to cause weight changes?

Weight changes are not universally categorized as a common side effect in official labeling. However, regulatory documents note that fluid retention and edema (swelling caused by too much fluid trapped in the body's tissues) have been reported with the NSAID component (Diclofenac).

Q: Does Dinal Plus have an effect on sleep patterns?

The official safety information may include certain effects on the nervous system. According to regulatory documents, insomnia (difficulty sleeping) or drowsiness are listed among the less frequent side effects.

Q: Are there any known interactions between Dinal Plus and common herbal supplements?

Regulatory bodies advise that there is limited safety information regarding the combination of this medicine with herbal remedies or supplements, as these products are generally not tested for drug interactions in the same way. Regulatory guidance suggests informing a healthcare professional about all co-administered products.

Q: What are the signs of a serious, but rare, side effect of Dinal Plus?

The official documentation highlights the potential for rare, serious reactions. Signs of gastrointestinal bleeding, for example, can include black or tarry stools or vomiting blood. Signs of hepatic failure (severe liver problems) can include yellowing of the skin or eyes, known as jaundice. Regulatory documents indicate that if these signs occur, they should be brought to the attention of a healthcare professional promptly.

Q: Can Dinal Plus affect the results of laboratory tests?

Official labeling references the need to monitor certain lab values during treatment. This monitoring is conducted because the medicine may potentially alter results for parameters like liver function, kidney function, and blood cell counts, as indicated in regulatory documentation.

Q: What is the shelf life of Dinal Plus?

The regulatory information specifies the product's shelf life, which is typically around 36 months from the date of manufacture. This is dependent on the product being stored correctly in its original container, as instructed by regulatory guidelines.

Q: Does Dinal Plus lose effectiveness over time?

Official labeling does not explicitly state that the medicine loses effectiveness (develops tolerance). However, official guidelines recommend that the patient's need for relief and their response to therapy be periodically reviewed by a healthcare professional, especially when considering prolonged use.

Q: Are there any specific foods I need to avoid while using Dinal Plus?

Official labeling primarily advises taking the medicine with or immediately after food to help reduce gastrointestinal irritation, but it does not mandate the avoidance of specific foods. However, chronic consumption of alcohol is specifically restricted due to the increased risk of liver toxicity related to the Paracetamol component.

Q: What happens if I forget to take Dinal Plus?

If a dose is missed, official patient information states that individuals should not take a double dose to make up for the one they missed. Instead, the instruction is to skip the missed dose entirely and continue with the regular dosing schedule, while maintaining the minimum required time interval between doses.

Q: What does the 'plus' in Dinal Plus refer to?

The 'Plus' in the name refers to the product's composition as a fixed-dose combination product. This means it contains two distinct active ingredients: Diclofenac and Paracetamol (Acetaminophen), designed to provide combined action.

Q: Are there different strengths of Dinal Plus available?

The medicine is generally supplied as a tablet in a specific fixed-dose strength for the two active ingredients. Information regarding other potential available strengths would be documented in the official prescribing information.

Q: Why do some people report feeling [vague feeling, e.g., tired] after starting Dinal Plus?

Official safety documentation notes that adverse effects are rare, but potential effects are categorized by the systems they affect. Effects such as drowsiness and tiredness have been reported and are included in the official list of less frequent nervous system side effects.

Q: What should I do if a side effect of Dinal Plus bothers me?

Official safety information indicates that individuals experiencing bothersome or concerning side effects should seek consultation with their licensed healthcare professional (such as a doctor or pharmacist) for guidance and evaluation.

Q: Are there different forms of Dinal Plus (e.g., tablet vs. liquid)?

According to official regulatory documents, Dinal Plus is primarily provided as a tablet, which is a solid oral dosage form intended to be swallowed whole. Other forms are not generally noted in the core prescribing information.

Q: Can Dinal Plus be taken at the same time as my daily vitamins?

Regulatory guidance suggests that patients inform a healthcare professional about all co-administered products, including daily vitamins and supplements. This ensures the professional is aware of everything being taken to manage potential drug-drug or drug-supplement interactions.

Q: Is it safe to stop Dinal Plus suddenly?

Official regulatory guidance states that discontinuation of the medicine should not be done suddenly without first discussing a plan with a doctor. This is particularly important if the patient has been on long-term treatment, to ensure continuity of care.

Q: Are there any restrictions on activity while using Dinal Plus?

Due to the potential for side effects such as dizziness or drowsiness (Nervous System Disorders), official warnings advise caution when performing activities that require full mental alertness, such as driving or operating machinery.

Q: Does Dinal Plus cause withdrawal symptoms?

This medicine is classified as an NSAID/Analgesic. While classic withdrawal symptoms are not typically reported in regulatory documents for this class, official guidance recommends that discontinuation be managed in consultation with a healthcare professional.

Q: Is there a generic version of Dinal Plus available?

As a fixed-dose combination containing two established active ingredients (Diclofenac and Paracetamol), generic versions of the component drugs are widely available. Generic availability for the specific combination under this brand name is dependent on patent status and regulatory approval.

Q: Why do official documents list so many potential side effects for Dinal Plus?

The official list of side effects includes all reported adverse events from clinical trials and post-marketing surveillance. This is done regardless of whether the event was directly caused by the medicine, in order to provide the fullest possible safety awareness to prescribers and patients.

Q: Does Dinal Plus help with [vague symptom related to its use]?

This medicine is indicated for the symptomatic relief of general aches and discomfort. Specifically, it addresses symptoms associated with inflammation, pain, and fever, as described in the official prescribing information for the combination product.

Q: Where can I find the official prescribing information for Dinal Plus?

The official prescribing information, such as the full Summary of Product Characteristics (SmPC) or FDA Drug Label, is a public document. It can be accessed via the public websites of national regulatory bodies, such as the FDA or the European Medicines Agency (EMA).

How should Dinal Plus be stored and disposed of?

How to Store and Dispose of Dinal Plus

Official regulatory guidelines dictate specific storage and disposal requirements for Dinal Plus tablets, a combination product containing Diclofenac and Paracetamol.


Storage Conditions

Dinal Plus must be stored at a temperature below 30°C and should be protected from light. To maintain stability until the expiry date, the medicine must be kept in its original container and must not be used if the blister is damaged. The product should be stored out of the reach and sight of children.


Disposal Instructions

Unused or expired Dinal Plus must not be disposed of via wastewater or household garbage. Regulatory instructions advise consulting a pharmacist for proper disposal methods, aligning with official pharmaceutical waste handling guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dinal Plus found in:

A-Z Index: